Clinical Trial Update: A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial investigating obinutuzumab with idasanutlin and venetoclax in relapsed/refractory follicular lymphoma and rituximab with idasanutlin and venet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma

Drugs mentioned

• Idasanutlin (Idasanutlin)
• Obinutuzumab (obinutuzumab)
• Rituximab (rituximab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Follicular Lymphoma, Lymphoma, Large B-Cell, Diffuse | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-07-27